Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
AstraZeneca is once again tapping the Shanghai-based developer Amoy Diagnostics for new companion tests to be paired up with its cancer medicines in China, Japan and the EU.